You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023424017
Dec 202360010
Jan 20247307
Feb 20246203
Mar 20244801
Apr 20246402
May 20245704
Jun 20247907
Jul 20242605
Aug 20246401
Sep 20247606
Oct 20245802
Nov 20244008
Dec 20243603
Jan 20253808
Feb 20251007
Mar 2025002
Apr 2025001
May 2025503
Jun 2025002
Total1220099